Intra-Cellular Therapies Receivables 2013-2024 | ITCI

Intra-Cellular Therapies receivables for the quarter ending December 31, 2024 were $0.167B, a 46.03% increase year-over-year.

  • Intra-Cellular Therapies receivables for 2024 were $0.167B, a 46.03% increase from 2023.
  • Intra-Cellular Therapies receivables for 2023 were $0.114B, a 51.64% increase from 2022.
  • Intra-Cellular Therapies receivables for 2022 were $0.075B, a 273.04% increase from 2021.

Intra-Cellular Therapies Receivables 2013-2024 | ITCI

  • Intra-Cellular Therapies receivables for 2024 were $0.167B, a 46.03% increase from 2023.
  • Intra-Cellular Therapies receivables for 2023 were $0.114B, a 51.64% increase from 2022.
  • Intra-Cellular Therapies receivables for 2022 were $0.075B, a 273.04% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.9B
Amgen (AMGN)$158.1B
Gilead Sciences (GILD)$134.2B
Vertex Pharmaceuticals (VRTX)$121.1B
Bristol Myers Squibb (BMY)$111.6B
CSL (CSLLY)$80.7B
GSK (GSK)$75.7B
Regeneron Pharmaceuticals (REGN)$75B
Argenex SE (ARGX)$38.9B
Alnylam Pharmaceuticals (ALNY)$32.4B
BioNTech SE (BNTX)$28.7B
BeiGene (ONC)$23.2B
Biogen (BIIB)$20B
Illumina (ILMN)$16.3B
Insmed (INSM)$15B
Genmab (GMAB)$14.5B
Genmab (GNMSF)$14.4B
Moderna (MRNA)$13.8B
Incyte (INCY)$13.6B
BioMarin Pharmaceutical (BMRN)$12.5B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Bio-Techne Corp (TECH)$10.4B
Vaxcyte (PCVX)$10.4B
Sarepta Therapeutics (SRPT)$10.2B
Exelixis (EXEL)$9.8B
Ascendis Pharma (ASND)$9.4B
Exact Sciences (EXAS)$9.3B
Bio-Rad Laboratories (BIO.B)$8.7B
QIAGEN (QGEN)$8.7B
Repligen (RGEN)$8.4B